|
1
|
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
|
Am J Transplant
|
2005
|
1.36
|
|
2
|
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.
|
Am J Transplant
|
2005
|
1.13
|
|
3
|
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
|
Clin Transplant
|
2006
|
0.86
|